Ocular Therapeutix, Inc. (OCUL) is a Biotechnology company in the Healthcare sector, currently trading at $8.76. It has a SharesGrow Score of 49/100, indicating a mixed investment profile with 2 out of 7 criteria passed.
Analyst consensus target is OCUL = $26 (+191.1% upside).
Valuation: OCUL trades at a trailing Price-to-Earnings (P/E) of -7.2 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 1.22.
Financials: revenue is $52M, +1.3%/yr average growth. Net income is $266M (loss), growing at -68.1%/yr. Net profit margin is -513.2% (negative). Gross margin is 87.3% (-3.9 pp trend).
Balance sheet: total debt is $80M against $654M equity (Debt-to-Equity (D/E) ratio 0.12, conservative). Current ratio is 15.39 (strong liquidity). Debt-to-assets is 9.9%. Total assets: $808M.
Analyst outlook: 16 / 18 analysts rate OCUL as buy (89%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 88/100 (Pass), Growth 30/100 (Fail), Past 0/100 (Fail), Health 67/100 (Partial), Moat 53/100 (Partial), Future 94/100 (Pass), Income 10/100 (Fail).
